281 related articles for article (PubMed ID: 35052910)
1. An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by
Gatti M; Viaggi B; Rossolini GM; Pea F; Viale P
Antibiotics (Basel); 2021 Dec; 11(1):. PubMed ID: 35052910
[TBL] [Abstract][Full Text] [Related]
2. An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients.
Gatti M; Viaggi B; Rossolini GM; Pea F; Viale P
Expert Rev Anti Infect Ther; 2022 Mar; 20(3):331-352. PubMed ID: 34488527
[TBL] [Abstract][Full Text] [Related]
3. An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by
Gatti M; Viaggi B; Rossolini GM; Pea F; Viale P
Infect Drug Resist; 2021; 14():2461-2498. PubMed ID: 34234476
[TBL] [Abstract][Full Text] [Related]
4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
5. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams.
Gatti M; Pea F
Expert Rev Anti Infect Ther; 2023 Feb; 21(2):149-166. PubMed ID: 36655779
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
7. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
[TBL] [Abstract][Full Text] [Related]
8. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
[TBL] [Abstract][Full Text] [Related]
9. [Occurrence of alert pathogens in hospital environment Part II. Multidrug-resistant non-fermenting bacilli].
Paluchowska P; Skałkowska M; Spelak A; Budak A
Med Dosw Mikrobiol; 2012; 64(1):45-53. PubMed ID: 22808729
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapy of Severe Infections Caused by
Gatti M; Viaggi B; Rossolini GM; Pea F; Viale P
Microorganisms; 2023 Feb; 11(2):. PubMed ID: 36838359
[TBL] [Abstract][Full Text] [Related]
11. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
[TBL] [Abstract][Full Text] [Related]
12. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
Shanthi M; Sekar U
J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
Mohanty S; Maurya V; Gaind R; Deb M
J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
[TBL] [Abstract][Full Text] [Related]
14. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).
Paul M; Carrara E; Retamar P; Tängdén T; Bitterman R; Bonomo RA; de Waele J; Daikos GL; Akova M; Harbarth S; Pulcini C; Garnacho-Montero J; Seme K; Tumbarello M; Lindemann PC; Gandra S; Yu Y; Bassetti M; Mouton JW; Tacconelli E; Rodríguez-Baño J
Clin Microbiol Infect; 2022 Apr; 28(4):521-547. PubMed ID: 34923128
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Biedenbach DJ; Giao PT; Hung Van P; Su Minh Tuyet N; Thi Thanh Nga T; Phuong DM; Vu Trung N; Badal RE
Clin Ther; 2016 Sep; 38(9):2098-105. PubMed ID: 27612610
[TBL] [Abstract][Full Text] [Related]
16. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
18. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB
Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047
[TBL] [Abstract][Full Text] [Related]
19. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
Falagas ME; Kastoris AC; Karageorgopoulos DE; Rafailidis PI
Int J Antimicrob Agents; 2009 Aug; 34(2):111-20. PubMed ID: 19403273
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
